scispace - formally typeset
T

Tomonori Sumida

Researcher at Hiroshima University

Publications -  18
Citations -  540

Tomonori Sumida is an academic researcher from Hiroshima University. The author has contributed to research in topics: Carcinoma & Metastasis. The author has an hindex of 7, co-authored 18 publications receiving 505 citations.

Papers
More filters
Journal ArticleDOI

Mesenchymal stem cells enhance growth and metastasis of colon cancer.

TL;DR: Collectively, MSCs migrate and differentiate into CAFs in tumor stroma, and they promote growth and metastasis of colon cancer by enhancing angiogenesis, migration and invasion and by inhibiting apoptosis of tumor cells.
Journal ArticleDOI

Expression of platelet-derived growth factor (PDGF)-B and PDGF-receptor β is associated with lymphatic metastasis in human gastric carcinoma.

TL;DR: The data indicate that secretion of PDGF‐B by gastric carcinoma cells and expression ofPDGF‐Rβ by tumor‐associated stromal cells are associated with lymphatic metastasis.
Journal ArticleDOI

Stroma-directed imatinib therapy impairs the tumor-promoting effect of bone marrow-derived mesenchymal stem cells in an orthotopic transplantation model of colon cancer

TL;DR: The data suggest that blockade of PDGF signaling pathways influences the interaction between bone marrow‐derived MSCs and tumor cells in the tumor microenvironment and, hence, inhibits the progressive growth of colon cancer.
Journal ArticleDOI

Anti-stromal therapy with imatinib inhibits growth and metastasis of gastric carcinoma in an orthotopic nude mouse model.

TL;DR: Administration of PDGF‐R tyrosine kinase inhibitor in combination with irinotecan appears to impair the progressive growth of gastric carcinoma by blockade of PD GF‐R signaling pathways in stromal cells.
Journal ArticleDOI

Antibodies to Helicobacter pylori and CagA protein are associated with the response to antibacterial therapy in patients with H. pylori-positive API2-MALT1-negative gastric MALT lymphoma.

TL;DR: Measurement of titers of serum antibodies to H. pylori and CagA protein may be useful for predicting the response to eradication therapy in patients with H.pylori‐positive API2–MALT1‐negative gastric MALT lymphoma.